IQV IQVIA Holdings, Inc. Common Stock
NYSE · Life Sciences Tools & Services · Wyświetl na SEC EDGAR ↗ zamknij Paź 6, 2026 10-K/10-Q Lip 28, 2026IQV Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
IQV Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
O IQVIA Holdings, Inc. Common Stock Przegląd firmy z Wikipedii
IQVIA Holdings, Inc. is an American health information technology and clinical research company headquartered in Durham, North Carolina. The company provides clinical research services, healthcare analytics, technology solutions, and commercial outsourcing services to pharmaceutical, biotechnology, medical device, and healthcare organizations worldwide.
IQVIA operates through three business segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Through its technology and analytics business, the company maintains access to more than one billion supposedly anonymized patient records globally, and provides healthcare data, analytics, and software services to life science organizations, health care centers like hospitals, and pharmacists worldwide. This participates in extending their access to personal health data around the globe.
The company was formed in 2016 through the merger of Quintiles, a contact research organization, and IMS Health, a healthcare data and analytics provider. The combined company operated as QuintilesIMS before adopting the name IQVIA in 2017. The IQVIA name is a combination of: I (IMS Health), Q (Quintiles), and VIA (by way of).
History
The company operates three divisions: Technology & Analytics (40% of 2024 revenues), focused on health information technology with access to 1.2 billion unique non-identified patient records globally, offers cloud-based customer relationship management application software as well as analytics consulting services all to the healthcare industry; Research & Development (55% of 2024 revenues), which is a contract research organization that handles all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, post-approval services, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics; and Contract Sales & Medical (5% of 2024 revenues), which offers contract sales to healthcare providers and patient engagement services.
IMS Health
The original name of the company was Intercontinental Marketing Statistics, hence the IMS name. IMS Health's corporate headquarters is located in Danbury, Connecticut, United States. The company's chairman and CEO is Ari Bousbib.
In 1998, the parent company, Cognizant Corporation, split into two companies: IMS Health and Nielsen Media Research. After this restructuring, Cognizant Technology Solutions became a public subsidiary of IMS Health
In 2002, IMS Health acquired Cambridge Pharma Consultancy, a privately held international firm that provides strategic advice to pharmaceutical management.
In 2002, IMS Health acquired the Rosenblatt Klauber Group, a privately held international consultancy that provides forecasting, opportunity assessment & management development services to pharmaceutical companies.
In 2003, acquired Marketing Initiatives, a specialist in healthcare facility profile data, and Data Niche Associates, a provider of rebate validation services for Medicaid and managed care. In 2003, IMS Health sold its entire 56% stake in Cognizant and both companies are separated into two independent entities as IMS Health and Cognizant
In 2004, United Research China Shanghai was acquired, providing coverage of China's consumer health market.
In 2005, acquired PharMetrics, a U.S. provider of patient-centric integrated claims data.
In 2006, acquired the Life Sciences practice of Strategic Decisions Group, a portfolio strategy consultant to the life sciences industry.
In 2007, IMS Health acquired IHS and MedInitiatives, providers of healthcare data management analytics and technology services. That same year, ValueMedics Research was acquired, extending IMS Health's health economics and outcomes research capabilities.
In 2007, ranked in the Businessweek 50. This list represents "best in class" companies from the ten economic sectors that make up the S&P 500.
In 2008, named to the World's Most Admired Companies list by Fortune. The company received the recognition again in 2010.
In 2008, acquired RMBC, a provider of national pharmaceutical market intelligence and analytics in Russia.
In 2008, acquired the Skura professional services group, based out of Mississauga, Ontario, Canada and specialized in data integration, consulting and services in business intelligence platforms to pharmaceutical and healthcare clients in North America and Europe.
In 2009, named to the Dow Jones Sustainability North America Index in recognition of the company's economic, environmental and social performance among the largest 600 North American companies.
In February 2010, IMS Health was taken private by TPG Capital, CPP Investment Board, and Leonard Green & Partners.
In 2010, acquired Brogan, Inc., a privately held market research and consulting firm serving the Canada healthcare market.
In 2011, expanded its specialty and patient-level data assets in the United States with the acquisition of SDI Health. Also that year, the company acquired Ardentia Ltd in the UK, and Med-Vantage in the United States to build on its payer services in those markets.
In 2012, acquired PharmARC Analytic Solutions Pvt. Ltd, a Bangalore-based analytics company.
In 2012, acquired DecisionView, a software solutions company that helps life sciences organizations plan and track patient enrollment for clinical trials and TTC, a benchmarking solutions and analytics company that helps clients plan for and negotiate the costs of clinical trials. Also in 2012, the company purchased PharmaDeals Ltd., a provider of online information about business transactions, licensing, and mergers and acquisitions activity within the pharmaceutical industry.
In 2013, acquired several companies to expand its portfolio of SaaS products: Incential Software, a provider of sales performance management technology services; 360 Vantage, which delivers multi-channel CRM software capabilities; Appature, which offers a relationship marketing platform; and Semantelli, a provider of social media analytics for the global healthcare industry.
In May 2015, IMS increased its software development capability by acquiring Dataline Software Ltd, a bespoke software development company and big data research specialist in the UK.
In April 2015, IMS Health completed the purchase of Cegedim's Customer Relationship Management (CRM) software and Strategic Data business for €396 million. Cegedim acquired the software and related business when it purchased Dendrite International in 2007.
In August 2015, IMS Health completed the purchase of Boston Biomedical Consultants, a provider of market data and market research covering the in vitro Diagnostics market
In May 2016, the company announced it would merge with Quintiles IMS Health shareholders received 0.384 shares of Quintiles common stock for each share of IMS Health common stock they held, leaving the split of ownership at 51.4% IMS and 48.6% Quintiles. The merger was completed in October and the resulting company was a $17.6 billion company called QuintilesIMS.
On November 6, 2017, the company adopted the new name of IQVIA.
Quintiles
Quintiles was the world's largest provider of biopharmaceutical development and commercial outsourcing services. The company offered clinical data management, clinical trial execution services, pharmaceuticals, drug development, financial partnering, and commercialization expertise to companies in the biotechnology, pharmaceutical and healthcare sectors.
In 1982, Dennis Gillings founded and incorporated Quintiles Transnational in North Carolina. Quintiles Transnational established Quintiles Pacific Inc. and Quintiles Ireland Ltd. in 1990. In 1991 Quintiles GmbH was established in Germany and Quintiles Laboratories Ltd. was established in Atlanta, Georgia. In September 1996, Quintiles purchased Innovex Ltd. of Britain for $747.5 million in stock. Quintiles went public in 1997 and completed a successful secondary stock offering.
In 1974, Dennis Gillings signs the first contract to provide statistical and data management consulting for pharmaceutical clients.
In 1982, Quintiles, Inc., is incorporated in North Carolina.
In 1990, Quintiles Pacific Inc. and Quintiles Ireland Ltd. are established.
In 1991, Quintiles GmbH is established in Germany; Quintiles Laboratories Ltd. is established in Atlanta, Georgia.
In 1996, Quintiles buys Innovex Ltd. and BRI International Inc., becoming the world's largest CRO.
In 1997, Quintiles goes public, completing a successful secondary stock offering.
In 1998, Quintiles becomes the first company in the industry to break the $1 billion mark, when it reports net revenues of $1.19 billion.
In 1999, the company joins the S&P 500 Index.
In 2003, the Board of Directors agrees to merge with Pharma Services Holdings Inc; Quintiles becomes a private company.
In 2009, Quintiles opens new corporate headquarters in Durham, North Carolina.
In 2010, Quintiles opens new European headquarters in the UK and establishes operations in East Africa.
In 2011, Quintiles buys Advion Biosciences, a bioanalytical lab based out of Ithaca, New York.
In 2013, Quintiles filed for an IPO on 15 February in order to go public again; Quintiles begins trading on the New York Stock Exchange (NYSE) under ticker symbol Q."
Merger of IMS Health and Quintiles
In October 2016, Quintiles merged with IMS Health to form QuintilesIMS. In November 2017, the company adopted the new name of IQVIA.
The company is ranked 282nd on the Fortune 500 and 680th on the Forbes Global 2000.
Controversies
IMS Health's business of collecting and selling pharmaceutical sales data, even though they say it is anonymized, was under scrutiny from both the media and the legal system.
IMS Health v. Ayotte was a free speech case involving IMS Health.
Sorrell v. IMS Health Inc. was a case about physician-data privacy, which went to the U.S. Supreme Court. The court ruled in favor of the company.
IQVIA was contracted by the UK government's Office of National Statistics to provide data on the prevalence of COVID-19 infection in the population. Some users of the survey reported problems contacting IQVIA and arranging for testing. The problems with how the survey results were collected were criticised for potentially leading to biased data by New Scientist.
On July 17, 2023, the Federal Trade Commission sued to block IQVIA’s acquisition of Propel Media alleging in an administrative complaint that the acquisition would give IQVIA a market-leading position in health care programmatic advertising and would raise health-care prices for consumers. In December 2023, U.S. District Court Judge Edgardo Ramos issued an order granting the FTC’s motion for preliminary injunction to block the merger. Speaking in favor of the FTC, Ramos said, "The FTC has shown that there is a reasonable probability that the proposed acquisition will substantially impair competition in the relevant market and that the equities weigh in favor of injunctive relief." An administrative trial was scheduled to start on January 18, 2024. However, on January 5, 2024, IQVIA and Propel Media announced that they had mutually agreed to abandon the proposed merger.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | IQV | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | 32.3średnia z 5 lat ≈35.9 | ≈35.9 | 31.1 | Niedowartościowany | |
| P/S (TTM) | 2.5średnia z 5 lat ≈2.8 | ≈2.8 | 5.4 | Niedowartościowany | |
| P/B (MRQ) | 6.9średnia z 5 lat ≈6.8 | ≈6.8 | 6.9 | Niedowartościowany | |
| EV / EBITDA (TTM) | 16.8średnia z 5 lat ≈17.7 | ≈17.7 | 24.2 | Niedowartościowany | |
| Cena / FCF (TTM) | 19.6średnia z 5 lat ≈22.1 | ≈22.1 | · | · | |
| Cena / Przepływy pieniężne (TTM) | 15.2średnia z 5 lat ≈16.4 | ≈16.4 | 25.7 | Niedowartościowany | |
| EV / Przychody (TTM) | 3.3średnia z 5 lat ≈3.6 | ≈3.6 | · | · | |
| EV / FCF (TTM) | 26.0średnia z 5 lat ≈28.5 | ≈28.5 | · | · | |
| Cena / Wartość księgowa materialna (MRQ) | 30.1 | · | · | · | |
| PEG Ratio (Współczynnik PEG) | ≈0.8 | · | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | IQV | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża Operacyjna (TTM) | 13.0%średnia z 5 lat ≈12.7% | ≈12.7% | 18.0% | Słaby | |
| Marża EBITDA (TTM) | 19.9%średnia z 5 lat ≈20.4% | ≈20.4% | 18.6% | Słaby | |
| Marża przed opodatkowaniem (TTM) | 9.3%średnia z 5 lat ≈9.6% | ≈9.6% | 18.9% | Słaby | |
| Marża Zysku Netto (TTM) | 8.1%średnia z 5 lat ≈8.2% | ≈8.2% | 15.8% | Słaby | |
| ROA (TTM) | 4.7%średnia z 5 lat ≈4.7% | ≈4.7% | 11.5% | Słaby | |
| ROE (TTM) | 23.0%średnia z 5 lat ≈20.2% | ≈20.2% | 18.4% | Najwyższa półka | |
| ROIC | 8.3%średnia z 5 lat ≈8.2% | ≈8.2% | 13.8% | Słaby |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | IQV | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | 2.6średnia z 5 lat ≈2.2 | ≈2.2 | 0.2 | Wysokie zadłużenie | |
| Wskaźnik bieżący (MRQ) | 0.7średnia z 5 lat ≈0.9 | ≈0.9 | 1.6 | Niska płynność | |
| Wskaźnik Szybkości (MRQ) | 0.6średnia z 5 lat ≈0.7 | ≈0.7 | 0.7 | Niska płynność | |
| Dług długoterminowy / Kapitał własny (MRQ) | 2.2średnia z 5 lat ≈2.1 | ≈2.1 | 0.5 | Wysokie zadłużenie | |
| Interest Coverage (Pokrycie odsetek) | 3.0średnia z 5 lat ≈3.5 | ≈3.5 | 8.3 | Niska płynność |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | IQV | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 5.9%średnia z 5 lat ≈7.7% | ≈7.7% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 4.2%średnia z 5 lat ≈5.8% | ≈5.8% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 7.5% | · | · | · | |
| EPS YoY | 4.7%średnia z 5 lat ≈59.3% | ≈59.3% | · | · | |
| Net Income YoY (Zysk Netto R/R) | -0.95%średnia z 5 lat ≈56.8% | ≈56.8% | · | · | |
| EPS CAGR 3Y (CAGR z EPS 3 lata) | 11.1%średnia z 5 lat ≈32.7% | ≈32.7% | · | · | |
| EPS CAGR 5Y (CAGR z EPS 5 lat) | 40.5% | · | · | · | |
| Net Income CAGR 3Y (CAGR z zysku netto 3 lata) | 7.6%średnia z 5 lat ≈29.8% | ≈29.8% | · | · | |
| Net Income CAGR 5Y (CAGR z zysku netto 5 lat) | 37.3% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | IQV | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.6średnia z 5 lat ≈0.6 | ≈0.6 | 0.6 | Zgodnie z | |
| Receivables Turnover (Rotacja należności) | 4.9średnia z 5 lat ≈5.0 | ≈5.0 | 5.5 | Słaby | |
| Revenue / Employee (Przychody / pracownika) | ≈$173.5K | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Lip 20, 2026 | $3.15 | $3.06 | 2.9% |
| 31 marca 2026 | $2.90 | $2.85 | 1.9% | |
| 31 grudnia 2025 | $3.42 | $3.43 | -0.34% | |
| 30 września 2025 | $3.00 | $3.00 | -0.04% | |
| 30 czerwca 2025 | $2.81 | $2.80 | 0.45% | |
| 31 marca 2025 | $2.70 | $2.66 | 1.6% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.31B | $15.40B | $14.98B | $14.41B | $13.87B | $11.36B | $11.09B | $10.41B | $9.70B | $6.82B | $5.74B | $5.46B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $4.62B | $3.24B | $2.71B | $2.66B | |
| R&D Expense | · | · | · | · | · | · | · | · | · | · | $3M | $6M | |
| SG&A Expense | $2.00B | $1.99B | $2.05B | $2.07B | $1.96B | $1.79B | $1.73B | $1.72B | $1.62B | $1.02B | $815M | $781M | |
| Operating Income | $2.18B | $2.20B | $1.98B | $1.80B | $1.39B | $731M | $777M | $741M | $665M | $576M | $646M | $590M | |
| Interest Expense | $729M | $670M | $672M | $416M | $375M | $416M | $447M | $414M | $346M | $144M | $101M | $101M | |
| Interest Income | $45M | $47M | $36M | $13M | $6M | $6M | $9M | $8M | $7M | $4M | $4M | $4M | |
| Other Non-op | $99M | $90M | $124M | $-33M | $130M | $65M | $37M | $-5M | $-13M | $11M | $-2M | $8M | |
| Pretax Income | $1.59B | $1.67B | $1.46B | $1.36B | $1.13B | $373M | $352M | $328M | $294M | $416M | $539M | $501M | |
| Income Tax | $252M | $301M | $101M | $260M | $163M | $72M | $116M | $59M | $-992M | $325M | $159M | $149M | |
| Net Income | $1.36B | $1.37B | $1.36B | $1.09B | $966M | $279M | $191M | $259M | $1.28B | $72M | $387M | $357M | |
| EPS (Basic) | $7.91 | $7.57 | $7.39 | $5.82 | $5.05 | $1.46 | $0.98 | $1.27 | $5.86 | $0.48 | $3.15 | $2.78 | |
| EPS (Diluted) | $7.84 | $7.49 | $7.29 | $5.72 | $4.95 | $1.43 | $0.96 | $1.24 | $5.74 | $0.47 | $3.08 | $2.72 | |
| Shares (Basic) | 171,900,000 | 181,300,000 | 183,800,000 | 187,600,000 | 191,400,000 | 191,300,000 | 195,100,000 | 203,700,000 | 217,800,000 | 149,100,000 | 123,000,000 | 128,000,000 | |
| Shares (Diluted) | 173,500,000 | 183,400,000 | 186,300,000 | 190,600,000 | 195,000,000 | 195,000,000 | 199,600,000 | 208,200,000 | 222,600,000 | 152,000,000 | 125,600,000 | 131,100,000 | |
| EBITDA | $3.33B | $3.32B | $3.10B | $2.93B | $2.66B | $2.02B | $1.98B | $1.88B | $1.73B | $931M | $774M | $711M |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.98B | $1.70B | $1.38B | $1.22B | $1.37B | $1.81B | $837M | $891M | $959M | $1.20B | $977M | $867M | |
| Short-term Investments | $161M | $141M | $120M | $93M | $111M | $88M | $62M | $47M | $46M | $40M | · | · | |
| Receivables | $3.40B | $3.20B | $3.38B | $2.92B | $2.55B | $2.41B | $2.58B | $2.39B | $2.10B | $1.71B | $1.17B | $975M | |
| Prepaid Expense | $162M | $154M | $141M | $151M | $156M | $159M | $138M | $151M | $146M | $123M | $51M | $45M | |
| Other Current Assets | · | · | · | · | · | · | · | $322M | $259M | $235M | $83M | $92M | |
| Current Assets | $6.25B | $5.83B | $5.60B | $4.98B | $4.76B | $5.09B | $4.13B | $3.87B | $3.55B | $3.34B | $2.41B | $2.15B | |
| PP&E (Net) | $533M | $535M | $523M | $532M | $497M | $482M | $458M | $434M | $440M | $406M | $188M | $190M | |
| PP&E (Gross) | $1.44B | $1.35B | $1.33B | $1.37B | $1.26B | $1.16B | $1.05B | $1.00B | $923M | $769M | $510M | $496M | |
| Accum. Depreciation | $905M | $819M | $803M | $840M | $765M | $673M | $597M | $567M | $483M | $363M | $322M | $306M | |
| Goodwill | $16.62B | $14.71B | $14.57B | $13.92B | $13.30B | $12.65B | $12.16B | $11.80B | $11.85B | $10.73B | $720M | $464M | |
| Intangibles | $4.96B | $4.50B | $4.84B | $4.82B | $4.94B | $5.21B | $5.51B | $5.95B | $6.59B | $6.39B | $368M | $280M | |
| Total Assets | $29.94B | $26.90B | $26.68B | $25.34B | $24.69B | $24.56B | $23.25B | $22.55B | $22.86B | $21.21B | $3.93B | $3.30B | |
| Accounts Payable | · | · | · | · | · | · | · | $437M | $322M | $250M | $145M | $109M | |
| Accrued Liabilities | $2.97B | $2.95B | $2.85B | $2.67B | $2.36B | $2.23B | $1.94B | $1.86B | $1.66B | $1.49B | $761M | $734M | |
| Current Liabilities | $8.34B | $6.96B | $6.49B | $5.58B | $5.24B | $4.56B | $3.94B | $3.53B | $3.16B | $2.71B | $1.59B | $1.47B | |
| Capital Leases | $225M | $173M | $223M | $264M | $313M | $371M | $396M | · | · | · | $18.0K | $14.0K | |
| Deferred Tax | $179M | $196M | $202M | $464M | $410M | $338M | $646M | $627M | $786M | $2.04B | · | $62M | |
| Other Non-current Liabilities | $688M | $668M | $698M | $671M | $649M | $633M | $456M | $418M | $440M | $402M | $183M | $184M | |
| Total Liabilities | $23.31B | $20.83B | $20.57B | $19.57B | $18.65B | $18.28B | $16.99B | $15.60B | $14.61B | $12.35B | $4.26B | $4.00B | |
| Long-term Debt | $15.72B | $13.98B | $13.67B | $12.75B | $12.12B | $12.53B | $11.64B | $11.01B | $10.27B | $7.22B | $2.50B | $2.31B | |
| Total Debt | $15.72B | $13.98B | $13.67B | $12.75B | $12.12B | $12.53B | $11.64B | $11.01B | $10.22B | $7.20B | $2.47B | $2.29B | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | $144M | |
| Retained Earnings | $7.42B | $6.07B | $4.69B | $3.33B | $2.24B | $1.28B | $998M | $807M | $538M | $-399M | $-462M | $-789M | |
| Treasury Stock | $11.36B | $10.10B | $8.74B | $7.74B | $6.57B | $6.17B | $5.73B | $4.77B | $3.37B | $1.00B | · | · | |
| AOCI | $-943M | $-1.04B | $-867M | $-727M | $-406M | $-205M | $-311M | $-224M | $49M | $-570M | $-111M | $-59M | |
| Stockholders' Equity | $6.50B | $6.07B | $6.11B | $5.76B | $6.04B | $6.28B | $6.26B | $6.71B | $8.00B | $8.63B | $-564M | $-704M | |
| Liabilities + Equity | $29.94B | $26.90B | $26.68B | $25.34B | $24.69B | $24.56B | $23.25B | $22.55B | $22.86B | $21.21B | $3.93B | $3.30B | |
| Shares Outstanding | 169,600,000 | 258,200,000 | 257,200,000 | 256,400,000 | 255,800,000 | 254,700,000 | 253,000,000 | 251,500,000 | 249,500,000 | 248,300,000 | 119,400,000 | 124,100,000 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1.14B | $1.11B | $1.12B | $1.13B | $1.26B | $1.29B | $1.20B | $1.14B | $1.01B | $289M | $128M | $121M | |
| Stock-based Comp | $247M | $206M | $217M | $194M | $170M | $95M | $146M | $113M | $106M | $106M | $38M | $30M | |
| Deferred Tax | $-180M | $-129M | $-269M | $-115M | $-138M | $-176M | $-157M | $-177M | $-1.22B | $115M | $18M | $-6M | |
| Amort. of Intangibles | $984M | $965M | $974M | $970M | $1.12B | $1.15B | $1.07B | $1.02B | $886M | $210M | $67M | $58M | |
| Restructuring | $105M | $67M | $84M | $28M | $20M | $52M | $75M | $68M | $63M | $71M | $30M | $9M | |
| Other Non-cash | $83M | $152M | $-282M | $-40M | $680M | $474M | $35M | $-82M | $-240M | $241M | $-95M | $-69M | |
| Operating Cash Flow | $2.65B | $2.72B | $2.15B | $2.26B | $2.94B | $1.96B | $1.42B | $1.25B | $970M | $860M | $476M | $433M | |
| CapEx | $603M | $602M | $649M | $674M | $640M | $616M | $582M | $459M | $369M | $164M | $78M | $83M | |
| Investing Cash Flow | $-2.31B | $-1.44B | $-1.60B | $-2.01B | $-2.10B | $-796M | $-1.19B | $-810M | $-1.19B | $1.73B | · | · | |
| Stock Repurchased | $1.24B | $1.35B | $992M | $1.17B | $406M | $447M | $949M | $1.41B | $2.62B | $1.10B | $515M | $415M | |
| Net Stock Activity | $-1.24B | $-1.35B | $-992M | $-1.17B | $-406M | $-447M | $-949M | $-1.41B | $-2.62B | $-1.10B | $-515M | $-415M | |
| Financing Cash Flow | $-150M | $-878M | $-382M | $-329M | $-1.24B | $-217M | $-276M | $-452M | $-72M | $-2.28B | · | · | |
| Net Change in Cash | $278M | $326M | $160M | $-150M | $-448M | $977M | $-54M | $-68M | $-239M | $221M | $110M | $90M | |
| Taxes Paid | · | $295M | $340M | $255M | $222M | $209M | $215M | $211M | $195M | $106M | $121M | $139M | |
| Free Cash Flow | $2.05B | $2.11B | $1.50B | $1.59B | $2.30B | $1.34B | $835M | $795M | $601M | $696M | $397M | $349M | |
| Levered FCF | $1.44B | $1.56B | $875M | $1.25B | $1.98B | $1.01B | $535M | $455M | $-777M | $656M | $326M | $420M |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.4% | 14.3% | 13.2% | 12.5% | 10.0% | 6.4% | 7.0% | 7.1% | 7.4% | 9.3% | 11.3% | 10.8% | |
| Net Margin | 8.3% | 8.9% | 9.1% | 7.6% | 7.0% | 2.5% | 1.7% | 2.5% | 13.4% | 1.7% | 6.8% | 6.5% | |
| Pretax Margin | 9.8% | 10.8% | 9.7% | 9.5% | 8.1% | 3.3% | 3.2% | 3.1% | 3.4% | 7.0% | 9.4% | 9.2% | |
| EBITDA Margin | 20.4% | 21.5% | 20.7% | 20.3% | 19.1% | 17.8% | 17.8% | 18.1% | 17.8% | 13.5% | 13.5% | 13.0% | |
| ROA | 4.8% | 5.1% | 5.2% | 4.4% | 3.9% | 1.2% | 0.83% | 1.1% | 6.0% | 0.92% | 10.7% | 11.2% | |
| ROE | 21.6% | 22.6% | 22.9% | 18.5% | 15.7% | 4.5% | 3.0% | 3.5% | 15.6% | 2.9% | -61.1% | -52.0% | |
| ROIC | 8.3% | 9.0% | 9.3% | 7.9% | 6.6% | 3.2% | 2.9% | 3.4% | 15.6% | 1.1% | 23.9% | 26.1% |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.7 | 0.8 | 0.9 | 0.9 | 0.9 | 1.1 | 1.0 | 1.1 | 1.2 | 1.2 | 1.5 | 1.5 | |
| Quick Ratio | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 | 1.0 | 1.1 | 1.3 | 1.3 | |
| Debt / Equity | 2.4 | 2.3 | 2.2 | 2.2 | 2.0 | 2.1 | 1.9 | 1.6 | 1.3 | 0.8 | -4.4 | -3.3 | |
| LT Debt / Equity | 2.1 | 2.1 | 2.1 | 2.2 | 2.0 | 2.1 | 1.9 | 1.6 | 1.2 | 0.8 | -4.3 | -3.3 | |
| Interest Coverage | 3.0 | 3.3 | 2.9 | 4.3 | 3.7 | 1.8 | 1.7 | 1.8 | 2.1 | 4.5 | 6.4 | -5.9 |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | 0.4 | 0.5 | 1.6 | 1.7 | |
| Receivables Turnover | 4.9 | 4.7 | 4.8 | 5.3 | 5.6 | 4.6 | 4.5 | 4.6 | 5.3 | 4.8 | 5.4 | 5.7 |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $38.34 | $34.45 | $33.67 | $31.04 | $31.70 | $31.39 | $31.22 | $26.70 | $32.50 | $34.77 | $-4.73 | $-5.67 | |
| Revenue / Share | $94.01 | $84.00 | $80.43 | $75.60 | $71.15 | $58.25 | $55.55 | $50.01 | $43.75 | $45.25 | $45.67 | $41.65 | |
| Cash Flow / Share | $15.30 | $14.81 | $11.54 | $11.86 | $15.09 | $10.05 | $7.10 | $6.02 | $4.36 | $5.66 | $3.79 | $3.29 | |
| Cash / Share | $11.67 | $9.66 | $7.58 | $6.55 | $7.17 | $9.49 | $4.35 | $3.54 | $3.84 | $4.82 | $8.19 | $6.99 | |
| EPS (TTM) | $7.84 | $7.49 | $7.29 | $5.72 | $4.95 | $1.43 | $0.96 | $1.24 | $5.74 | $0.47 | $3.08 | $2.72 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 5.9% | 2.8% | 4.0% | 3.9% | 22.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 4.2% | 3.5% | 9.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 7.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 4.7% | 2.7% | 27.5% | 15.6% | 246.2% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 11.1% | 14.8% | 72.1% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 40.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -0.95% | 1.1% | 24.5% | 12.9% | 246.2% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 7.6% | 12.4% | 69.5% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $16.31B | $15.40B | $14.98B | $14.41B | $13.87B | $11.36B | $11.09B | $10.41B | $9.70B | $6.82B | $5.74B | $5.46B | |
| Net Income TTM | $1.36B | $1.37B | $1.36B | $1.09B | $966M | $279M | $191M | $259M | $1.28B | $72M | $387M | $357M | |
| Market Cap | $38.23B | $34.61B | $42.00B | $38.05B | $53.78B | $34.26B | $29.71B | $29.22B | $24.43B | $18.88B | $8.20B | $7.31B | |
| Enterprise Value | $51.81B | $46.75B | $54.17B | $49.49B | $64.42B | $44.89B | $40.46B | $39.29B | $33.65B | $24.85B | $9.69B | $8.73B | |
| P/E | 28.8 | 26.2 | 31.7 | 35.8 | 57.0 | 125.3 | 160.9 | 93.7 | 17.1 | 161.8 | 22.3 | 21.6 | |
| P/S | 2.3 | 2.2 | 2.8 | 2.6 | 3.9 | 3.0 | 2.7 | 2.8 | 2.5 | 2.8 | 1.4 | 1.3 | |
| P/B | 5.9 | 5.7 | 6.9 | 6.6 | 8.9 | 5.7 | 4.9 | 4.4 | 3.0 | 2.2 | -14.5 | -10.4 | |
| P / Cash Flow | 14.4 | 12.7 | 19.5 | 16.8 | 18.3 | 17.5 | 21.0 | 23.3 | 25.2 | 22.0 | 17.2 | 16.9 | |
| P / FCF | 18.6 | 16.4 | 28.0 | 24.0 | 23.4 | 25.5 | 35.6 | 36.8 | 40.6 | 27.1 | 20.6 | 20.9 | |
| EV / EBITDA | 15.6 | 14.1 | 17.5 | 16.9 | 24.2 | 22.2 | 20.4 | 20.9 | 19.4 | 26.7 | 12.5 | 12.3 | |
| EV / FCF | 25.3 | 22.1 | 36.1 | 31.2 | 28.0 | 33.4 | 48.5 | 49.4 | 56.0 | 35.7 | 24.4 | 25.0 | |
| EV / Revenue | 3.2 | 3.0 | 3.6 | 3.4 | 4.6 | 4.0 | 3.6 | 3.8 | 3.5 | 3.6 | 1.7 | 1.6 | |
| Earnings Yield | 3.5% | 3.8% | 3.1% | 2.8% | 1.8% | 0.80% | 0.62% | 1.1% | 5.9% | 0.62% | 4.5% | 4.6% |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.37B | $4.15B | $4.36B | $4.10B | $4.02B | $3.83B | $3.96B | $3.90B | $3.81B | $3.74B | $3.87B | $3.74B | $3.73B | $3.65B | $3.74B | $3.56B | |
| Gross Profit | · | · | · | · | · | · | · | $915M | $863M | $827M | · | $862M | $850M | $802M | · | $812M | |
| SG&A Expense | $574M | $502M | $468M | $514M | $509M | $508M | $453M | $522M | $509M | $508M | $556M | $502M | $482M | $513M | $583M | $517M | |
| Operating Income | $506M | $514M | $627M | $553M | $506M | $496M | $626M | $550M | $520M | $506M | $501M | $481M | $524M | $471M | $379M | $472M | |
| Interest Expense | $197M | $192M | $193M | $189M | $182M | $165M | $171M | $170M | $163M | $166M | $181M | $181M | $169M | $141M | $128M | $108M | |
| Interest Income | $7M | $10M | $11M | $13M | $10M | $11M | $11M | $13M | $12M | $11M | $12M | $14M | $4M | $6M | $6M | $4M | |
| Other Non-op | $-12M | $-4M | $94M | $31M | $-11M | $-15M | $78M | $-44M | $67M | $-11M | $47M | $35M | $16M | $26M | $18M | $-8M | |
| Pretax Income | $301M | $328M | $537M | $408M | $323M | $323M | $544M | $349M | $436M | $340M | $373M | $349M | $375M | $362M | $275M | $360M | |
| Income Tax | $60M | $59M | $59M | $76M | $56M | $61M | $112M | $65M | $75M | $49M | $-102M | $51M | $81M | $71M | $48M | $70M | |
| Net Income | $256M | $274M | $514M | $331M | $266M | $249M | $437M | $285M | $363M | $288M | $469M | $303M | $297M | $289M | $227M | $283M | |
| EPS (Basic) | $1.54 | $1.63 | $3.00 | $1.94 | $1.55 | $1.42 | $2.43 | $1.57 | $1.99 | $1.58 | $2.56 | $1.66 | $1.61 | $1.56 | $1.23 | $1.52 | |
| EPS (Diluted) | $1.53 | $1.61 | $2.97 | $1.93 | $1.54 | $1.40 | $2.41 | $1.55 | $1.97 | $1.56 | $2.54 | $1.63 | $1.59 | $1.53 | $1.21 | $1.49 | |
| Shares (Basic) | 166,100,000 | 168,400,000 | · | 170,200,000 | 171,800,000 | 175,700,000 | · | 182,100,000 | 182,200,000 | 181,900,000 | · | 182,900,000 | 184,400,000 | 185,800,000 | · | 186,500,000 | |
| Shares (Diluted) | 167,300,000 | 169,800,000 | · | 171,700,000 | 173,200,000 | 177,400,000 | · | 184,200,000 | 184,300,000 | 184,300,000 | · | 185,500,000 | 186,700,000 | 188,600,000 | · | 189,400,000 | |
| EBITDA | $798M | $802M | · | $839M | $782M | $761M | · | $828M | $789M | $770M | · | $778M | $783M | $724M | · | $720M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.91B | $1.95B | $1.98B | $1.81B | $2.04B | $1.74B | $1.70B | $1.57B | $1.54B | $1.44B | · | $1.22B | $1.38B | $1.49B | · | $1.27B | |
| Short-term Investments | $171M | $156M | $161M | $158M | $149M | $136M | $141M | $140M | $133M | $131M | · | $108M | $110M | $104M | · | $87M | |
| Receivables | $3.35B | $3.35B | $3.40B | $3.27B | $3.34B | $3.27B | $3.20B | $3.20B | $3.25B | $3.43B | · | $3.23B | $3.14B | $3.06B | · | $2.64B | |
| Prepaid Expense | $220M | $167M | $162M | $177M | $200M | $166M | $154M | $195M | $191M | $173M | · | $177M | $179M | $165M | · | $176M | |
| Current Assets | $6.23B | $6.22B | $6.25B | $5.98B | $6.34B | $5.91B | $5.83B | $5.63B | $5.62B | $5.65B | · | $5.21B | $5.33B | $5.33B | · | $4.75B | |
| PP&E (Net) | $547M | $516M | $533M | $525M | $536M | $533M | $535M | $513M | $503M | $513M | · | $498M | $510M | $520M | · | $507M | |
| PP&E (Gross) | · | · | $1.44B | · | · | · | $1.35B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $905M | · | · | · | $819M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $16.60B | $16.54B | $16.62B | $15.95B | $15.61B | $15.03B | $14.71B | $15.09B | $14.48B | $14.52B | $14.57B | $14.29B | $14.18B | $14.02B | $13.92B | $13.18B | |
| Intangibles | $4.75B | $4.80B | $4.96B | $4.71B | $4.60B | $4.50B | $4.50B | $4.73B | $4.61B | $4.72B | · | $4.91B | $4.94B | $4.76B | · | $4.72B | |
| Total Assets | $29.88B | $29.68B | $29.94B | $28.73B | $28.63B | $27.32B | $26.90B | $27.18B | $26.40B | $26.57B | · | $25.98B | $26.04B | $25.74B | · | $24.22B | |
| Accrued Liabilities | · | · | $2.97B | · | · | · | $2.95B | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $8.81B | $8.33B | $8.34B | $8.51B | $7.57B | $7.18B | $6.96B | $6.99B | $6.62B | $6.45B | · | $6.59B | $6.54B | $6.66B | · | $5.25B | |
| Capital Leases | $242M | $232M | $225M | $233M | $210M | $177M | $173M | $188M | $192M | $204M | · | $217M | $242M | $255M | · | $259M | |
| Deferred Tax | $173M | $159M | $179M | $207M | $216M | $197M | $196M | $128M | $149M | $164M | · | $365M | $367M | $421M | · | $560M | |
| Other Non-current Liabilities | $645M | $617M | $688M | $698M | $671M | $676M | $668M | $612M | $632M | $595M | · | $679M | $703M | $641M | · | $561M | |
| Total Liabilities | $23.58B | $23.33B | $23.31B | $22.44B | $22.85B | $21.34B | $20.83B | $20.21B | $19.68B | $20.23B | · | $20.17B | $20.29B | $19.81B | · | $18.88B | |
| Long-term Debt | $16.00B | $15.83B | $15.72B | $14.96B | $15.49B | $14.33B | $13.98B | $13.51B | $13.26B | $13.54B | · | $13.63B | $13.78B | $13.18B | · | $12.39B | |
| Total Debt | $16.00B | $15.83B | · | $14.96B | $15.49B | $14.33B | · | $13.51B | $13.26B | $13.54B | · | $13.63B | $13.78B | $13.18B | · | $12.39B | |
| Retained Earnings | $7.96B | $7.70B | $7.42B | $6.91B | $6.58B | $6.31B | $6.07B | $5.63B | $5.34B | $4.98B | · | $4.22B | $3.92B | $3.62B | · | $3.11B | |
| Treasury Stock | $12.32B | $11.91B | $11.36B | $11.14B | $11.14B | $10.53B | $10.10B | $8.94B | $8.74B | $8.74B | · | $8.51B | $8.36B | $7.87B | · | $7.71B | |
| AOCI | $-964M | $-968M | $-943M | $-928M | $-882M | $-978M | $-1.04B | $-826M | $-949M | $-911M | · | $-903M | $-760M | $-731M | · | $-898M | |
| Stockholders' Equity | $6.17B | $6.22B | $6.50B | $6.16B | $5.78B | $5.98B | $6.07B | $6.97B | $6.71B | $6.34B | · | $5.80B | $5.75B | $5.93B | $5.76B | $5.35B | |
| Liabilities + Equity | $29.88B | $29.68B | $29.94B | $28.73B | $28.63B | $27.32B | $26.90B | $27.18B | $26.40B | $26.57B | · | $25.98B | $26.04B | $25.74B | · | $24.22B | |
| Shares Outstanding | 164,600,000 | 166,900,000 | 169,600,000 | 170,300,000 | 170,000,000 | 174,100,000 | 176,100,000 | 181,600,000 | 182,300,000 | 182,200,000 | 257,200,000 | 182,500,000 | 183,100,000 | 185,500,000 | 256,400,000 | 185,800,000 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $292M | $288M | $317M | $286M | $276M | $265M | $303M | $278M | $269M | $264M | $316M | $297M | $259M | $253M | $357M | $248M | |
| Stock-based Comp | $95M | $65M | $60M | $55M | $60M | $72M | $48M | $54M | $48M | $56M | $45M | $47M | $50M | $75M | $58M | $61M | |
| Deferred Tax | $-36M | $-38M | $-48M | $-46M | $-45M | $-41M | $-15M | $-34M | $-14M | $-66M | $-152M | $-47M | $-43M | $-27M | $-63M | $-24M | |
| Restructuring | $63M | $51M | $24M | $20M | $32M | $29M | $-4M | $28M | $28M | $15M | $17M | $30M | $20M | $17M | $13M | $4M | |
| Other Non-cash | · | $29M | · | · | · | $23M | · | · | · | $-20M | · | · | · | $-173M | · | · | |
| Operating Cash Flow | $558M | $618M | $735M | $908M | $443M | $568M | $885M | $721M | $588M | $522M | $747M | $583M | $402M | $417M | $560M | $863M | |
| CapEx | $198M | $127M | $174M | $136M | $151M | $142M | $164M | $150M | $143M | $145M | $179M | $146M | $160M | $164M | $171M | $165M | |
| Investing Cash Flow | $-381M | $-196M | $-1.10B | $-550M | $-346M | $-305M | $-310M | $-599M | $-221M | $-314M | $-212M | $-573M | $-596M | $-222M | $-477M | $-717M | |
| Stock Repurchased | $398M | $552M | $212M | $0 | $657M | $375M | $1.15B | $200M | $0 | $0 | $229M | $144M | $490M | $129M | $65M | $210M | |
| Net Stock Activity | · | $-552M | · | · | · | $-375M | · | · | · | $0 | · | · | · | $-129M | · | · | |
| Financing Cash Flow | $-214M | $-433M | $535M | $-572M | $145M | $-258M | $-375M | $-137M | $-260M | $-106M | $-420M | $-144M | $95M | $87M | $-193M | $-251M | |
| Net Change in Cash | $-38M | $-33M | $166M | $-225M | $299M | $38M | $130M | $27M | $101M | $68M | $152M | $-158M | $-112M | $278M | $-58M | $-154M | |
| Free Cash Flow | · | $491M | · | · | · | $426M | · | · | · | $377M | · | · | · | $253M | · | · | |
| Levered FCF | · | $334M | · | · | · | $292M | · | · | · | $235M | · | · | · | $140M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | · | · | 23.5% | 22.6% | 22.1% | · | 23.1% | 22.8% | 22.0% | · | 22.8% | |
| Operating Margin | 11.6% | 12.4% | · | 13.5% | 12.6% | 13.0% | · | 14.1% | 13.6% | 13.5% | · | 12.9% | 14.1% | 12.9% | · | 13.2% | |
| Net Margin | 5.9% | 6.6% | · | 8.1% | 6.6% | 6.5% | · | 7.3% | 9.5% | 7.7% | · | 8.1% | 8.0% | 7.9% | · | 7.9% | |
| Pretax Margin | 6.9% | 7.9% | · | 10.0% | 8.0% | 8.4% | · | 9.0% | 11.4% | 9.1% | · | 9.3% | 10.1% | 9.9% | · | 10.1% | |
| EBITDA Margin | 18.3% | 19.3% | · | 20.5% | 19.5% | 19.9% | · | 21.2% | 20.7% | 20.6% | · | 20.8% | 21.0% | 19.8% | · | 20.2% | |
| ROA | 0.88% | 0.96% | · | 1.2% | 0.97% | 0.92% | · | 1.1% | 1.4% | 1.1% | · | 1.2% | 1.2% | 1.1% | · | 1.2% | |
| ROE | 4.3% | 4.5% | · | 5.0% | 4.3% | 4.0% | · | 4.5% | 5.8% | 4.7% | · | 5.4% | 5.3% | 4.9% | · | 5.1% | |
| ROIC | 1.8% | 1.9% | · | 2.1% | 2.0% | 2.0% | · | 2.2% | 2.2% | 2.2% | · | 2.1% | 2.1% | 2.0% | · | 2.1% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.7 | 0.7 | · | 0.7 | 0.8 | 0.8 | · | 0.8 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.8 | · | 0.9 | |
| Quick Ratio | 0.6 | 0.7 | · | 0.6 | 0.7 | 0.7 | · | 0.7 | 0.7 | 0.8 | · | 0.7 | 0.7 | 0.7 | · | 0.8 | |
| Debt / Equity | 2.6 | 2.5 | · | 2.4 | 2.7 | 2.4 | · | 1.9 | 2.0 | 2.1 | · | 2.3 | 2.4 | 2.2 | · | 2.3 | |
| LT Debt / Equity | 2.2 | 2.2 | · | 2.1 | 2.5 | 2.2 | · | 1.8 | 1.8 | 2.0 | · | 2.1 | 2.2 | 2.0 | · | 2.3 | |
| Interest Coverage | 2.6 | 2.7 | · | 2.9 | 2.8 | 3.0 | · | 3.2 | 3.2 | 3.0 | · | 2.7 | 3.1 | 3.3 | · | 4.4 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.3 | 1.2 | 1.1 | · | 1.2 | 1.2 | 1.2 | · | 1.3 | 1.3 | 1.3 | · | 1.4 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $37.49 | $37.27 | · | $36.17 | $33.99 | $34.33 | · | $38.36 | $36.83 | $34.82 | · | $31.81 | $31.39 | $31.98 | · | $28.78 | |
| Revenue / Share | $26.11 | $24.45 | · | $23.88 | $23.19 | $21.58 | · | $21.15 | $20.69 | $20.28 | · | $20.14 | $19.97 | $19.36 | · | $18.81 | |
| Cash Flow / Share | · | $3.64 | · | · | · | $3.20 | · | · | · | $2.83 | · | · | · | $2.21 | · | · | |
| Cash / Share | $11.60 | $11.67 | · | $10.65 | $11.99 | $9.99 | · | $8.66 | $8.47 | $7.93 | · | $6.71 | $7.55 | $8.05 | · | $6.86 | |
| EPS (TTM) | $8.04 | $8.05 | · | $7.28 | $6.90 | $7.33 | · | $7.62 | $7.70 | $7.32 | · | $5.96 | $5.82 | $5.57 | · | $6.13 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $16.98B | $16.63B | · | $15.90B | $15.70B | $15.50B | · | $15.31B | $15.15B | $15.07B | · | $14.86B | $14.68B | $14.49B | · | $14.31B | |
| Net Income TTM | $1.38B | $1.39B | · | $1.28B | $1.24B | $1.33B | · | $1.41B | $1.42B | $1.36B | · | $1.12B | $1.10B | $1.05B | · | $1.18B | |
| Market Cap | $31.80B | $28.46B | · | $32.35B | $26.79B | $30.69B | · | $43.03B | $38.55B | $46.08B | · | $35.91B | $41.16B | $36.89B | · | $33.66B | |
| Enterprise Value | $45.72B | $42.19B | · | $45.33B | $40.09B | $43.15B | · | $54.83B | $50.13B | $58.04B | · | $48.21B | $53.44B | $48.47B | · | $44.69B | |
| P/E | 24.0 | 21.2 | · | 26.1 | 22.8 | 24.1 | · | 31.1 | 27.5 | 34.5 | · | 33.0 | 38.6 | 35.7 | · | 29.5 | |
| P/S | 1.9 | 1.7 | · | 2.0 | 1.7 | 2.0 | · | 2.8 | 2.5 | 3.1 | · | 2.4 | 2.8 | 2.5 | · | 2.4 | |
| P/B | 5.2 | 4.6 | · | 5.3 | 4.6 | 5.1 | · | 6.2 | 5.7 | 7.3 | · | 6.2 | 7.2 | 6.2 | · | 6.3 | |
| P / Cash Flow | · | 46.1 | · | · | · | 54.0 | · | · | · | 88.3 | · | · | · | 88.5 | · | · | |
| EV / Revenue | 2.7 | 2.5 | · | 2.9 | 2.6 | 2.8 | · | 3.6 | 3.3 | 3.9 | · | 3.2 | 3.6 | 3.3 | · | 3.1 | |
| Dividend Yield | 1.8% | 2.0% | · | 1.8% | 2.1% | 1.8% | · | 1.3% | 1.5% | 1.2% | · | 1.6% | 1.4% | 1.5% | · | 1.7% | |
| Earnings Yield | 4.2% | 4.7% | · | 3.8% | 4.4% | 4.2% | · | 3.2% | 3.6% | 2.9% | · | 3.0% | 2.6% | 2.8% | · | 3.4% | |
| Annual Payout | $568M | $568M | · | $568M | $568M | $568M | · | $568M | $568M | $568M | · | $568M | $568M | $568M | · | $568M |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $16.31B | $15.40B | $14.98B | $14.41B | $13.87B |
| Marża Operacyjna % | 13.4% | 14.3% | 13.2% | 12.5% | 10.0% |
| Zysk netto | $1.36B | $1.37B | $1.36B | $1.09B | $966M |
| Rozwodniony EPS | $7.84 | $7.49 | $7.29 | $5.72 | $4.95 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 2.4 | 2.3 | 2.2 | 2.2 | 2.0 |
| Wskaźnik bieżący | 0.7 | 0.8 | 0.9 | 0.9 | 0.9 |
| Wskaźnik Szybkości | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $2.05B | $2.11B | $1.50B | $1.59B | $2.30B |
Właściciele instytucjonalni (13F) 1 166 emitentów · $34.4B łącznie · Na dzień 30 września 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 133 (-14 vs poprzedni kw.) | 104 (-64 vs poprzedni kw.) | 394 (-23 vs poprzedni kw.) | 434 (+39 vs poprzedni kw.) | +2.2M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $4 429 426 419 | 19 650 532 | 12,89% | Akcje |
| BlackRock, Inc. | $2 811 291 786 | 14 549 693 | 8,18% | Akcje |
| HARRIS ASSOCIATES L P | $2 354 159 681 | 12 183 830 | 6,85% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $2 107 074 341 | 10 905 053 | 6,13% | Akcje |
| STATE STREET CORP | $1 450 742 906 | 7 508 244 | 4,22% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1 449 535 087 | 7 501 993 | 4,22% | Akcje |
| JPMORGAN CHASE & CO | $1 186 696 291 | 6 139 775 | 3,45% | Akcje |
| Artisan Partners Limited Partnership | $916 526 317 | 4 743 434 | 2,67% | Akcje |
| Boston Partners | $865 495 912 | 4 466 016 | 2,52% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $857 164 506 | 4 454 134 | 2,49% | Akcje |
| Invesco Ltd. | $632 822 739 | 3 275 141 | 1,84% | Akcje |
| MORGAN STANLEY | $523 095 569 | 2 707 252 | 1,52% | Akcje |
| NORGES BANK | $437 632 480 | 2 264 944 | 1,27% | Akcje |
| FRANKLIN RESOURCES INC | $406 763 846 | 2 105 185 | 1,18% | Akcje |
| GOLDMAN SACHS GROUP INC | $376 739 643 | 1 949 797 | 1,10% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $335 332 933 | 1 735 452 | 0,98% | Akcje |
| NORTHERN TRUST CORP | $330 244 089 | 1 709 161 | 0,96% | Akcje |
| AQR CAPITAL MANAGEMENT LLC | $296 954 756 | 1 536 874 | 0,86% | Akcje |
| Longview Partners (Guernsey) LTD | $289 976 847 | 1 500 760 | 0,84% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $286 747 561 | 1 484 047 | 0,83% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $280 214 615 | 1 643 102 | 0,82% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $255 684 992 | 1 499 267 | 0,74% | Akcje |
| CIBC Private Wealth Group LLC | $250 474 554 | 1 318 704 | 0,73% | Akcje |
| LYRICAL ASSET MANAGEMENT LP | $243 436 719 | 1 259 894 | 0,71% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $241 535 241 | 1 250 053 | 0,70% | Akcje |
| CANADA PENSION PLAN INVESTMENT BOARD | $240 910 560 | 1 246 820 | 0,70% | Akcje |
| BANK OF AMERICA CORP /DE/ | $235 550 883 | 1 219 081 | 0,69% | Akcje |
| FMR LLC | $234 312 009 | 1 212 670 | 0,68% | Akcje |
| Orbis Allan Gray Ltd | $212 767 102 | 1 101 165 | 0,62% | Akcje |
| Legal & General Group Plc | $211 341 913 | 1 093 789 | 0,61% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $204 721 978 | 1 059 526 | 0,60% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $200 451 907 | 1 037 428 | 0,58% | Akcje |
| LAZARD ASSET MANAGEMENT LLC | $188 470 731 | 975 420 | 0,55% | Akcje |
| Amundi | $185 064 534 | 957 792 | 0,54% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $181 113 608 | 937 344 | 0,53% | Akcje |
| Bank of New York Mellon Corp | $180 295 799 | 933 111 | 0,52% | Akcje |
| Sumitomo Mitsui Trust Group, Inc. | $160 725 420 | 831 826 | 0,47% | Akcje |
| FIL Ltd | $158 246 601 | 818 997 | 0,46% | Akcje |
| CADIAN CAPITAL MANAGEMENT, LP | $157 619 601 | 815 752 | 0,46% | Akcje |
| ROYAL BANK OF CANADA | $154 182 000 | 797 956 | 0,45% | Akcje |
| AMERIPRISE FINANCIAL INC | $152 003 958 | 786 637 | 0,44% | Akcje |
| JARISLOWSKY, FRASER Ltd | $149 227 880 | 785 658 | 0,43% | Akcje |
| GREENHAVEN ASSOCIATES INC | $148 401 655 | 768 045 | 0,43% | Akcje |
| CIBC Bancorp USA Inc. | $144 647 217 | 747 031 | 0,42% | Akcje |
| 1832 Asset Management L.P. | $143 802 826 | 744 244 | 0,42% | Akcje |
| DEUTSCHE BANK AG\ | $143 074 192 | 740 473 | 0,42% | Akcje |
| Balyasny Asset Management L.P. | $135 333 607 | 700 412 | 0,39% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $121 523 014 | 628 936 | 0,35% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $113 104 610 | 585 374 | 0,33% | Akcje |
| Allianz Asset Management GmbH | $108 945 937 | 563 844 | 0,32% | Akcje |
Aktywiści i właściciele 5%+ 4 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Canada Pension Plan Investment Board, CPP Investment Board Private Holdings Inc. ×8 zgłoszenia | 13 sierpnia 2019 | · | Pierwotne zgłoszenie | · | SEC |
| TPG Group Holdings (SBS) Advisors, Inc., TPG Advisors VI, Inc., TPG Advisors V, Inc., TPG Biotech Advisors, Inc., David Bonderman, James G. Coulter ×9 zgłoszenia | 12 marca 2019 | · | Pierwotne zgłoszenie | Struktura kapitałowa | SEC |
| Quintiles Transnational Holdings Inc. | 13 maja 2016 | · | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
| OR | 13 maja 2016 | · | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 42 insiderów · 22 dyrektorzy generalni · 19 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Ari Bousbib | Chairman, Chief Executive Officer & President Power of Attorney | 29 lipca 2026 M | 835 941 | 0 | 11 | $-46 686 123 |
| Ronald E Bruehlman | EVP & Chief Financial Officer | 8 lutego 2026 F | 44 103 | 0 | 0 | $0 |
| Michael R. Mcdonnell | EVP and CFO | 5 lipca 2020 F | 18 966 | 0 | 0 | $0 |
| Richard W Staub | President, Research & Development Solutions Power of Attorney | 3 sierpnia 2026 S | 13 312 | 0 | 1 | $-1 279 740 |
| Bhavik Patel | President, MedTech and Consumer Health Power of Attorney | 31 lipca 2026 S | 1 348 | 0 | 1 | $-436 426 |
| Alistair Grenfell | President, Commercial Solutions | 9 lutego 2026 A | 24 124 | 0 | 0 | $0 |
| Kevin C Knightly | President, Corporate Strategy & Enterprise Networks | 28 lutego 2024 M | 652 | 0 | 0 | $0 |
| Constantinos Panagos | President, Research & Development Solutions | 19 września 2023 M | 14 250 | 0 | 0 | $0 |
| John D Ratliff | President and COO | 18 listopada 2013 X | 0 | 0 | 0 | $0 |
| Kevin K Gordon | EVP and COO | 9 czerwca 2016 X | 17 899 | 0 | 0 | $0 |
| James G. Berkshire | EVP, Global Infrastructure and Operations. Power of Attorney | 2 września 2026 M | 8 177 | 0 | 1 | $-697 228 |
| Keriann Cherofsky | SVP, Corporate Controller Power of Attorney | 29 lipca 2026 S | 2 989 | 0 | 1 | $-136 827 |
| Eric Sherbet | Executive Vice President, General Counsel Power of Attorney | 29 lipca 2026 S | 20 999 | 0 | 2 | $-2 124 600 |
| Bernd Haas | EVP, AI and Technology Solutions. | 13 lutego 2026 F | 24 394 | 0 | 0 | $0 |
| Michael J. Fedock | SVP, FP&A | 13 lutego 2026 F | 9 472 | 0 | 0 | $0 |
| Emmanuel N Korakis | SVP, Controller & Treasurer | 10 lutego 2022 A | 4 932 | 0 | 0 | $0 |
| Robert Parks | Sr Vice President, Controller | 2 sierpnia 2018 S | 1 195 | 0 | 0 | $0 |
| Iii James H Erlinger | Remarks: Executive Vice President, General Counsel & Corporate Secretary | 26 lutego 2018 X | 13 494 | 0 | 0 | $0 |
| Charles Edward Williams | Sr VP and Controller | 4 marca 2017 F | 3 494 | 0 | 0 | $0 |
| Thomas Pike | Vice Chair, Pres R&D Solutions | 3 października 2016 A | 185 460 | 0 | 0 | $0 |
| Derek M. Winstanly | Exec VP & Chief Cust & Gov Ofc | 13 lutego 2014 X | 229 500 | 0 | 0 | $0 |
| Michael I. Mortimer | Exec VP & Chief Admin Officer | 18 listopada 2013 S | 25 000 | 0 | 0 | $0 |
| Morris Leslie Wims | Dyrektor | 14 lipca 2026 A | 2 058 | 0 | 0 | $0 |
| Jim Fasano | Dyrektor | 14 lipca 2026 A | 1 063 | 0 | 0 | $0 |
| Colleen A Goggins | Dyrektor | 14 lipca 2026 A | 14 453 | 0 | 0 | $0 |
| John G Danhakl | Dyrektor | 14 lipca 2026 A | 30 612 | 0 | 0 | $0 |
| Sheila A Stamps | Dyrektor | 23 kwietnia 2026 A | 2 058 | 0 | 0 | $0 |
| John M. Leonard | Dyrektor | 23 kwietnia 2026 A | 16 946 | 0 | 0 | $0 |
| William G Kaelin Jr | Dyrektor | 23 kwietnia 2026 A | · | 0 | 0 | $0 |
| Carol Burt | Dyrektor | 23 kwietnia 2026 A | 7 533 | 0 | 0 | $0 |
| John Connaughton | Dyrektor | 5 lutego 2025 A | 1 047 | 0 | 0 | $0 |
| Ronald A Rittenmeyer | Dyrektor | 11 maja 2022 A | 13 533 | 0 | 0 | $0 |
| Michael J Evanisko | Dyrektor | 24 marca 2020 M | 11 850 | 0 | 0 | $0 |
| Jack M Greenberg | Dyrektor | 26 kwietnia 2018 A | 7 388 | 0 | 0 | $0 |
| Dennis B Ph D Gillings | Dyrektor | 28 sierpnia 2017 S | 84 067 | 0 | 0 | $0 |
| Annie H. Lo | Dyrektor | 12 maja 2016 P | 2 062 | 0 | 0 | $0 |
| Leonard D Schaeffer | Dyrektor | 5 maja 2016 A | 65 896 | 0 | 0 | $0 |
| Christopher R Gordon | Dyrektor | 5 sierpnia 2015 S | 9 944 017 | 0 | 0 | $0 |
| Mireille Gillings | Dyrektor | 19 maja 2015 X | 11 663 929 | 0 | 0 | $0 |
| Canada Pension Plan Investment Board | Posiadacz 10% | 18 września 2018 J | 1 569 600 | 0 | 0 | $0 |
| DENNIS & MIREILLE GILLINGS FOUNDATION | Posiadacz 10% | 19 maja 2015 S | 103 556 | 0 | 0 | $0 |
| Gillings Limited Partnership | Posiadacz 10% | 10 listopada 2014 S | 0 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 118 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| BSJQ · Invesco Exchange-Traded Self-Indexe… | 3,25% | 24 245 000 | 5 października 2026 | Dziennie |
| EPMV · Harbor ETF Trust | 2,33% | 465 NS | 31 lipca 2026 | N-PORT |
| EPMB · Harbor ETF Trust | 2,30% | 447 NS | 31 lipca 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 2,10% | 6 182 NS | 31 lipca 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 2,03% | 15 946 SH | 5 października 2026 | Dziennie |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1,71% | 661 NS | 31 lipca 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,66% | 56 235 SH | 5 października 2026 | Dziennie |
| NUMV · Nushares ETF Trust | 1,16% | 21 969 NS | 31 lipca 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,03% | 45 853 NS | 31 lipca 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,81% | 645 380 NS | 31 lipca 2026 | N-PORT |
| IYH · iShares Trust | 0,69% | 97 405 SH | 11 września 2026 | Dziennie |
| IMCV · iShares Trust | 0,60% | 26 943 SH | 11 września 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 0,58% | 80 727 NS | 31 lipca 2026 | N-PORT |
| PALC · Pacer Funds Trust | 0,56% | 5 014 NS | 31 lipca 2026 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0,56% | 1 072 113 SH | 19 sierpnia 2026 | Dziennie |
| IXJ · iShares Trust | 0,55% | 87 943 SH | 11 września 2026 | Dziennie |
| REVS · Columbia ETF Trust I | 0,53% | 7 502 NS | 31 lipca 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,48% | 510 171 SH | 19 sierpnia 2026 | Dziennie |
| CURE · Direxion Shares ETF Trust | 0,45% | 3 284 NS | 31 lipca 2026 | N-PORT |
| IWS · iShares Trust | 0,42% | 248 773 SH | 11 września 2026 | Dziennie |
| RECS · Columbia ETF Trust I | 0,34% | 85 117 NS | 31 lipca 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,34% | 96 513 NS | 31 lipca 2026 | N-PORT |
| IWR · iShares Trust | 0,32% | 681 998 SH | 11 września 2026 | Dziennie |
| VO · VANGUARD INDEX FUNDS | 0,31% | 3 616 975 SH | 19 sierpnia 2026 | Dziennie |
| IMCB · iShares Trust | 0,30% | 19 380 SH | 11 września 2026 | Dziennie |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,29% | 8 282 000 | 5 października 2026 | Dziennie |
| SIZE · iShares Trust | 0,28% | 4 721 SH | 11 września 2026 | Dziennie |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,27% | 5 305 NS | 31 lipca 2026 | N-PORT |
| XOEF · iShares Trust | 0,24% | 209 SH | 11 września 2026 | Dziennie |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,22% | 14 586 NS | 31 lipca 2026 | N-PORT |
| EVUS · iShares Trust | 0,22% | 3 214 SH | 11 września 2026 | Dziennie |
| EUSA · iShares, Inc. | 0,21% | 15 656 SH | 11 września 2026 | Dziennie |
| RSP · Invesco Exchange-Traded Fund Trust | 0,20% | 757 586 SH | 5 października 2026 | Dziennie |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,20% | 12 117 NS | 31 lipca 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0,19% | 127 563 NS | 31 lipca 2026 | N-PORT |
| SUSA · iShares Trust | 0,19% | 29 276 SH | 11 września 2026 | Dziennie |
| CATH · Global X Funds | 0,19% | 10 317 NS | 31 lipca 2026 | N-PORT |
| USXF · iShares Trust | 0,17% | 9 913 SH | 11 września 2026 | Dziennie |
| DFVX · Dimensional ETF Trust | 0,17% | 3 772 NS | 31 lipca 2026 | N-PORT |
| IETC · iShares U.S. ETF Trust | 0,16% | 4 238 SH | 11 września 2026 | Dziennie |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,15% | 180 000 | 5 października 2026 | Dziennie |
| IVE · iShares Trust | 0,14% | 276 912 SH | 11 września 2026 | Dziennie |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,14% | 5 408 SH | 5 października 2026 | Dziennie |
| IUSV · iShares Trust | 0,14% | 145 686 SH | 11 września 2026 | Dziennie |
| HAPI · Harbor ETF Trust | 0,14% | 2 834 NS | 31 lipca 2026 | N-PORT |
| VEGN · ETF Series Solutions | 0,13% | 995 NS | 31 lipca 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,13% | 12 666 NS | 31 lipca 2026 | N-PORT |
| SUSL · iShares Trust | 0,13% | 5 891 SH | 11 września 2026 | Dziennie |
| ILCV · iShares Trust | 0,12% | 6 457 SH | 11 września 2026 | Dziennie |
| ESGU · iShares Trust | 0,12% | 86 320 SH | 11 września 2026 | Dziennie |
| DSI · iShares Trust | 0,12% | 25 509 SH | 11 września 2026 | Dziennie |
| CHRI · Global X Funds | 0,12% | 41 NS | 31 lipca 2026 | N-PORT |
| VTV · VANGUARD INDEX FUNDS | 0,12% | 1 586 142 SH | 19 sierpnia 2026 | Dziennie |
| IQSU · New York Life Investments ETF Trust | 0,12% | 1 646 NS | 31 lipca 2026 | N-PORT |
| IWD · iShares Trust | 0,12% | 370 293 SH | 11 września 2026 | Dziennie |
| DXUV · Dimensional ETF Trust | 0,11% | 2 668 NS | 31 lipca 2026 | N-PORT |
| ESG · FlexShares Trust | 0,11% | 630 NS | 31 lipca 2026 | N-PORT |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,11% | 38 391 SH | 19 sierpnia 2026 | Dziennie |
| FAB · First Trust Exchange-Traded AlphaDE… | 0,10% | 732 NS | 31 lipca 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,10% | 204 603 NS | 31 lipca 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 2 938 SH | 5 października 2026 | Dziennie |
| MPLY · Strategy Shares | 0,09% | 63 NS | 31 lipca 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,09% | 100 463 SH | 19 sierpnia 2026 | Dziennie |
| DCOR · Dimensional ETF Trust | 0,09% | 12 595 NS | 31 lipca 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,09% | 33 100 SH | 5 października 2026 | Dziennie |
| USCL · iShares Trust | 0,08% | 8 924 SH | 11 września 2026 | Dziennie |
| PRF · Invesco Exchange-Traded Fund Trust | 0,08% | 30 948 SH | 5 października 2026 | Dziennie |
| TOPC · iShares Trust | 0,08% | 101 SH | 11 września 2026 | Dziennie |
| DFAU · Dimensional ETF Trust | 0,08% | 40 752 NS | 31 lipca 2026 | N-PORT |
| XVV · iShares Trust | 0,07% | 1 903 SH | 11 września 2026 | Dziennie |
| ACVF · ETF Opportunities Trust | 0,07% | 453 NS | 31 lipca 2026 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,07% | 4 438 SH | 5 października 2026 | Dziennie |
| IVV · iShares Trust | 0,07% | 2 103 687 SH | 11 września 2026 | Dziennie |
| PBP · Invesco Exchange-Traded Fund Trust | 0,07% | 980 SH | 5 października 2026 | Dziennie |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,06% | 26 816 SH | 5 października 2026 | Dziennie |
| ILCB · iShares Trust | 0,06% | 3 205 SH | 11 września 2026 | Dziennie |
| XRMI · Global X Funds | 0,06% | 136 NS | 31 lipca 2026 | N-PORT |
| XYLD · Global X Funds | 0,06% | 8 760 NS | 31 lipca 2026 | N-PORT |
| XTR · Global X Funds | 0,06% | 13 NS | 31 lipca 2026 | N-PORT |
| XYLG · Global X Funds | 0,06% | 171 NS | 31 lipca 2026 | N-PORT |
| BKLC · BNY Mellon ETF Trust | 0,06% | 14 509 NS | 31 lipca 2026 | N-PORT |
| IYY · iShares Trust | 0,06% | 7 256 SH | 11 września 2026 | Dziennie |
| PTLC · Pacer Funds Trust | 0,06% | 8 592 NS | 31 lipca 2026 | N-PORT |
| IWB · iShares Trust | 0,06% | 114 864 SH | 11 września 2026 | Dziennie |
| VOXP · Advisors Series Trust | 0,06% | 15 NS | 31 lipca 2026 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,06% | 22 801 NS | 31 lipca 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0,06% | 37 611 SH | 19 sierpnia 2026 | Dziennie |
| TOV · EA Series Trust | 0,06% | 665 NS | 31 lipca 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0,06% | 2 798 NS | 31 lipca 2026 | N-PORT |
| IWV · iShares Trust | 0,06% | 46 437 SH | 11 września 2026 | Dziennie |
| XCLR · Global X Funds | 0,06% | 9 NS | 31 lipca 2026 | N-PORT |
| ITOT · iShares Trust | 0,06% | 217 365 SH | 11 września 2026 | Dziennie |
| DFUS · Dimensional ETF Trust | 0,06% | 50 666 NS | 31 lipca 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,06% | 629 NS | 31 lipca 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0,06% | 4 015 NS | 31 lipca 2026 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0,05% | 130 SH | 5 października 2026 | Dziennie |
| ESGG · FlexShares Trust | 0,05% | 247 NS | 31 lipca 2026 | N-PORT |
| TOK · iShares Trust | 0,05% | 483 SH | 11 września 2026 | Dziennie |
| VOO · VANGUARD INDEX FUNDS | 0,05% | 4 333 695 SH | 19 sierpnia 2026 | Dziennie |
| VV · VANGUARD INDEX FUNDS | 0,05% | 194 924 SH | 19 sierpnia 2026 | Dziennie |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,05% | 27 436 SH | 19 sierpnia 2026 | Dziennie |
| CRBN · iShares Trust | 0,05% | 2 234 SH | 11 września 2026 | Dziennie |
| HCMT · Direxion Shares ETF Trust | 0,05% | 1 160 NS | 31 lipca 2026 | N-PORT |
| URTH · iShares, Inc. | 0,05% | 14 957 SH | 11 września 2026 | Dziennie |
| SPXL · Direxion Shares ETF Trust | 0,05% | 13 048 NS | 31 lipca 2026 | N-PORT |
| TILT · FlexShares Trust | 0,04% | 4 108 NS | 31 lipca 2026 | N-PORT |
| ACWI · iShares Trust | 0,04% | 52 954 SH | 11 września 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,04% | 5 300 282 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,04% | 14 020 SH | 19 sierpnia 2026 | Dziennie |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,03% | 141 334 SH | 19 sierpnia 2026 | Dziennie |
| DYNF · BlackRock ETF Trust | 0,02% | 29 557 SH | 11 września 2026 | Dziennie |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,02% | 3 211 SH | 5 października 2026 | Dziennie |
| NEAR · iShares U.S. ETF Trust | 0,01% | 400 000 SH | 9 września 2026 | Dziennie |
| VGHY · VANGUARD FIXED INCOME SECURITIES FU… | · | · | 15 lipca 2026 | Dziennie |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VGMS · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
IQV Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
12-miesięczny cel cenowy
19 analityków · 2026-10-05Średnia cel $288.74 +11,1%
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| IQV | $38.23B | 28.8 | 5.9% | 8.3% | 21.6% | · |
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | · |
| DHR | $161.82B | 45.3 | 2.9% | 14.7% | 7.1% | 59.1% |
| A | $41.43B | 32.0 | 6.7% | 18.8% | 20.6% | · |
| WAT | $22.62B | 35.3 | 7.0% | 20.3% | 27.2% | · |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | · |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | · |
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | · |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.